N-arylation of 3-alkoxypyrazoles, the case of the pyridines
摘要:
In the course of a research program focused on the preparation of libraries of new chemical entities derived from 3-alkoxypyrazoles, we studied their N-pyridylation using 2, 3 or 4-bromopyridines This was achieved using Cristau and Taillefer copper-catalyzed arylation method and mostly led to the 3-alkoxy-1H-pyrazol-1-yl pyridine isomer along with lesser amount of the alternative 5-alkoxy-1H-pyrazol-1-yl pyridine The structures of these isomers were often established via their chemical tansformations and sometimes recourse to unambiguous synthetic routes for comparison purposes The alternative use of 2-fluoropyridine-based arylation was also investigated and lifted some of the limitations encountered in the course of this study (C) 2010 Elsevier Ltd All rights reserved
New pyrazolones as 11b-HSD1 inhibitors for diabetes
申请人:Amrein Kurt
公开号:US20070049574A1
公开(公告)日:2007-03-01
Compounds of formula
as well as pharmaceutically acceptable salts and esters thereof, wherein R
1
to R
4
have the significance given in claim
1
can be used in the form of pharmaceutical compositions.
Alkoxypyrazoles and the process for their preparation
申请人:Institut Pasteur
公开号:EP2151433A1
公开(公告)日:2010-02-10
The present invention relates to a alkoxypyrazoles preparation process, and new alkoxypyrazole compounds.
本发明涉及一种烷氧基吡唑的制备方法,以及新的烷氧基吡唑化合物。
Substituted anthranilamides for controlling invertebrate pests
申请人:Finkelstein Lawrence Bruce
公开号:US20070203201A1
公开(公告)日:2007-08-30
This invention provides compounds of Formula I, and N-oxides and salts thereof
wherein A, B, R
1
through R
5
, R
7
through R
9
, X and Y are as defined in the disclosure.
Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula I. Also disclosed are compositions for controlling an invertebrate pest comprising the compounds of Formula I.
Compounds of formula
as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R4 have the significance given in claim 1 can be used in the form of pharmaceutical compositions.